Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

20/20 GeneSystems Awarded $750,000 NCI Contract

Published: Wednesday, February 26, 2014
Last Updated: Wednesday, February 26, 2014
Bookmark and Share
Award will see 20/20 develop companion diagnostic for targeted therapies in kidney cancer.

20/20 GeneSystems, Inc. announces that the NCI has awarded the company a cost-sharing Phase II Small Business Innovation and Research (SBIR) contract to develop, optimize, and validate (analytically and clinically) a test to help predict whether a patient with advanced stage kidney cancer (renal cell carcinoma) is likely to benefit from anti-angiogenic therapy. The anticipated end result is a diagnostic test that will indicate to oncologists the appropriate treatment for patients. 

With an estimated 65,000 new cases in the US in 2013 kidney cancer represents 3% of all cancers yet the disease is the 6th leading cancer death, with an estimated 13,600 deaths in 2013. Kidney cancer does not exhibit any symptoms at an early stage it therefore often remains undetected until it is advanced. Advanced renal cell carcinoma does not respond to chemotherapy and radiation. Three types of treatments are currently used: immunotherapy, anti-angiogenic agents, and mTOR inhibitors and no treatment is effective in more than a fraction of patients. Kidney cancer can progress very rapidly. Once the cancer is detected it is important to select the right treatment as quickly as possible. 

“There is a large unmet clinical need for an assay to identify kidney cancer patients likely to respond or not respond to a particular therapy. The early results which 20/20 presented last year are very promising. The 20/20 test would help guide treatment decisions and strategies so we can provide the best informed care to our patients,” says Sandy Srinivas, MD, Associate Professor of Oncology at the Stanford University School of Medicine. “There is a definite need for a companion diagnostic to predict response to anti-angiogenic drugs as there are other targeted therapies, with other mechanisms of action, which may be more suitable”. 

The development of the proof of concept development was funded by Phase I SBIR contract HHSN261201000135C from the National Cancer Institute and private funds. 


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

20/20 GeneSystems Acquires Rights to Lung Cancer Screening Test
The Company intends to develop a diagnostic that would help identify lung cancer.
Tuesday, December 20, 2005
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!